|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM367591456 |
| 003 |
DE-627 |
| 005 |
20241111231904.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240125s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1080/02786826.2023.2262004
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1597.xml
|
| 035 |
|
|
|a (DE-627)NLM367591456
|
| 035 |
|
|
|a (NLM)38268721
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ratliff, Katherine M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Impact of test methodology on the efficacy of triethylene glycol (Grignard Pure) against bacteriophage MS2
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 11.11.2024
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status PubMed-not-MEDLINE
|
| 520 |
|
|
|a The COVID-19 pandemic has raised interest in using chemical air treatments as part of a strategy to reduce the risk of disease transmission, but more information is needed to characterize their efficacy at scales translatable to applied settings and to develop standardized test methods for characterizing the performance of these products. Grignard Pure, a triethylene glycol (TEG) active ingredient air treatment, was evaluated using two different test protocols in a large bioaerosol test chamber and observed to inactivate bacteriophage MS2 in air (up to 99.9% at 90 min) and on surfaces (up to 99% at 90 min) at a concentration of approximately 1.2 - 1.5 mg/m3. Introducing bioaerosol into a TEG-charged chamber led to overall greater reductions compared to when TEG was introduced into a bioaerosol-charged chamber, although the differences in efficacy against airborne MS2 were only significant in the first 15 min. Time-matched control conditions (no TEG present) and replicate tests for each condition were essential for characterizing treatment efficacy. These findings suggest that chemical air treatments could be effective in reducing the air and surface concentrations of infectious pathogens in occupied spaces, although standard methods are needed for evaluating their efficacy and comparing results across studies. The potential health impacts of chronic exposure to chemicals should also be considered, but those were not evaluated here
|
| 650 |
|
4 |
|a Journal Article
|
| 700 |
1 |
|
|a Oudejans, Lukas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Archer, John
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Calfee, Worth
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gilberry, Jerome U
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hook, David Adam
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schoppman, William E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yaga, Robert W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brooks, Lance
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ryan, Shawn
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Aerosol science and technology : the journal of the American Association for Aerosol Research
|d 1989
|g 57(2023), 12 vom: 10. Nov., Seite 1178-1185
|w (DE-627)NLM09822025X
|x 0278-6826
|7 nnns
|
| 773 |
1 |
8 |
|g volume:57
|g year:2023
|g number:12
|g day:10
|g month:11
|g pages:1178-1185
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1080/02786826.2023.2262004
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 57
|j 2023
|e 12
|b 10
|c 11
|h 1178-1185
|